Earnings Outlook For Halozyme Therapeutics
Portfolio Pulse from Benzinga Insights
Halozyme Therapeutics (NASDAQ:HALO) is set to release its latest quarterly earnings report on November 6, 2023. Analysts estimate an earnings per share (EPS) of $0.74. The company's past performance shows a pattern of beating EPS estimates, but this has sometimes been followed by a drop in share price. Over the last 52-week period, HALO shares are down 24.54%.
November 03, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Halozyme Therapeutics is expected to report an EPS of $0.74 for Q3 2023. Despite beating EPS estimates in the past, the company's share price has often dropped afterwards. The stock is down 24.54% over the last 52 weeks.
The company has a history of beating EPS estimates, but this has often been followed by a drop in share price. Given the negative returns over the last 52 weeks, investors may be bearish on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100